AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and Chief Executive Officer, will present an overview of the Company at the Cowen and Company 29th Annual Healthcare Conference on Tuesday, March 17, 2009 at 8:45 a.m. ET. The conference is being held in Boston, MA, March 16-19, 2009.

Dr. Pereira’s presentation will include an update on the timelines and potential design of the Company’s clinical development programs for Feraheme™ (ferumoxytol injection) in patients with iron deficiency anemia due to abnormal uterine bleeding, oncology and other diseases. In addition, Dr. Pereira will include an update on recent discussions with the U.S. Food and Drug Administration (FDA) regarding the status of the Feraheme new drug application and the Company’s efforts to resolve the observations noted by the FDA during its recent inspection of the Company’s manufacturing facility.

A live audio webcast of the presentation will be accessible through the Investors section of the Company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until March 31, 2009.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Feraheme is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia and as a diagnostic agent for vascular-enhanced magnetic resonance imaging to assess peripheral arterial disease.